Filing Details
- Accession Number:
- 0000899243-20-033216
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-09 20:00:09
- Reporting Period:
- 2020-12-07
- Accepted Time:
- 2020-12-09 20:00:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1351288 | Gw Pharmaceuticals Plc | GWPH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1754125 | B. Douglas Snyder | Sovereign House, Vision Park, Histon Cambridge X0 CB24 9BZ | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2020-12-07 | 4,800 | $10.84 | 22,104 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-12-07 | 9,444 | $10.95 | 23,660 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-12-07 | 3,984 | $11.02 | 8,676 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-12-07 | 5,076 | $11.11 | 3,600 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-12-07 | 1,200 | $11.19 | 2,400 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-12-07 | 2,400 | $11.30 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020.
- Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
- Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($130.0325 per ADS). These shares were sold in multiple transactions at prices ranging from $129.69 per ADS (or $10.81 per ordinary share) to $130.50 per ADS (or $10.88 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($131.3749 per ADS). These shares were sold in multiple transactions at prices ranging from $130.83 per ADS (or $10.90 per ordinary share) to $131.81 per ADS (or $10.98 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($132.2066 per ADS). These shares were sold in multiple transactions at prices ranging from $131.87 per ADS (or $10.99 per ordinary share) to $132.30 per ADS (or $11.03 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($133.2948 per ADS). These shares were sold in multiple transactions at prices ranging from $132.90 per ADS (or $11.08 per ordinary share) to $133.64 per ADS (or $11.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($134.3200 per ADS). These shares were sold in multiple transactions at prices ranging from $134.32 per ADS (or $11.19 per ordinary share) to $134.32 per ADS (or $11.19 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($135.6500 per ADS). These shares were sold in multiple transactions at prices ranging from $135.65 per ADS (or $11.30 per ordinary share) to $135.65 per ADS (or $11.30 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
